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a–e Bangladesh
A nine-year-old Bangladeshi male with a body mass index 16.5 kg/m2 presented with progressive tuberous
xanthomata on both auricles, elbows, gluteal regions and legs since birth. His father, paternal and maternal grandfather
had xanthelasma, however, the siblings had none. Examination of the cardiovascular system was otherwise normal.
Laboratory investigations were performed on several occasions since he was 4 years of age and revealed extreme
dyslipidaemia with very high total cholesterol (TC), low density lipoprotein cholesterol (LDL-C), triglycerides (TG),
apolipoprotein B (Apo-B) and lipoprotein(a), and low apolipoprotein-A (Apo-A) levels. Repeated combination of lipid
lowering agents with cholestyramine, atorvastatin and ezetimibe were virtually ineffective in improving the lipid
profiles. Supplementation therapy with niacin also had no effect. In view of the unavailability in Bangladesh of lipid
apheresis, the cornerstone of therapy, the management of the case becomes complicated.
 2012 King Saud University. Production and hosting by Elsevier B.V. All rights reserved.
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In children and adolescents, hyperlipidaemia isusually secondary but extreme elevations of
low density lipoprotein (LDL) are frequently asso-
ciated with primary or genetic hyperlipidaemias.
Atherosclerotic process has been observed to be-
gin in early life [1] and certain pediatric diseases
are linked to accelerated atherosclerosis resulting
in clinical coronary events. A classical example of
genetic hyperlipidaemia is familial hypercholes-
terolemia which is characterized by markedly ele-
vated lipid levels, especially LDL cholesterol. It
has been observed that familial hypercholesterol-1016–7315  2012 King Saud University.
Production and hosting by Elsevier B.V. All rights reserved.
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http://dx.doi.org/10.1016/j.jsha.2012.06.264emia (FH) is the most common primary hyperlip-
idemia linked to cardiovascular abnormalities in
childhood [2], often in the first decade of life.
Therefore, the identification and management of
FH in children is of great importance.
Here, a case of familial hypercholesterolemia
with extremely high cholesterol levels has been
described. The hyperlipidaemia was refractory to
conventional lipid lowering agents administered
repeatedly. Lipid apheresis is considered another
option for the treatment of such cases with FH.
Unfortunately, it is not yet readily available. The
difficulties in treating severe dyslipidaemia in
absence of lipid-apheresis are illustrated here.Production and hosting by Elsevier
Figure 1. Tuberous xanthoma at the ankle joint of the boy.
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A nine-year-old boy from Chittagong, Bangla-
desh, whose body mass index (BMI) was 16.5 kg/
m2, presentedwithmultiple yellowishplaques con-
sistentwith tuberous xanthoma indifferent parts of
body, including auricles, back of the elbows, gluteal
regions and legs (Fig. 1 andFig. 2). The lesionswere
present at birth, and increasedgradually in size and
number over time. A systemic examination of the
cardiovascular system revealed otherwise normal
findings. There was no organomegaly revealed.
There was no history of premature coronary ar-
tery disease or death in the family. His maternal
grandfather underwent coronary artery bypass
grafting (CABG) at the age of 60. His father,
grandfathers (both paternal and maternal) had
xanthelasmata. However, his two siblings, one
13 years of age and the other 18 years of age, had
no such lesions.Investigations
Lipid profile performed initially 4 years of age
and repeated on several occasions revealedTable 1. Lipid profiles of the patient done on different occasions.
Date TC
(mg/dL)
LDL
(mg/d
20 April 2004 769 517
18 July 2004 (after 3 months’ atorvastatin
and cholestyramine)
681 192
20 July 2009 446 392
27 September 2009 (after 3 months’
atorvastatin and ezetimibe)
597 494
04 Novemebr 2009 648 617
a Reference value: 0.85–2.0 g/L.
b Reference value: 0.79–1.27 g/L.
c Reference value: <0.3 g/L.persistent hypercholesterolemia as presented in
Table 1.
Blood sugar, thyroid function tests (T3, T4 and
TSH), liver function tests (AST, ALT and GGT)
and serum creatinine and urinalysis were normal.
Free T4 levels were also normal. The chest X-ray,
ECG, echocardiogram and duplex ultrasound scan
of carotid, aorta, peripheral and renal arteries re-
vealed normal findings. A sonogram showed
echogenic infiltration in the tendo achilles with
loss of normal tendon architecture (Fig. 3).Differential diagnosis
The National Cholesterol Education Program
(NCEP) Expert Panel on Blood Cholesterol Levels
in Children and Adolescents [3] and the National
Health And Nutrition Examination Survey
(NHANES) [4] had recommended the parameters
for high apolipoprotein A and apolipoprotein B.
Compared to the recommended levels as indi-
cated by NCEP [3] and NHANES[4], the patient
presented here had very high total cholesterol
(TC), low density lipoprotein cholesterol (LDL-
C), high triglycerides (TG), apolipoprotein B
(Apo-B) and apolipoprotein A (Apo-A) levels.
The abnormal lipid profiles together with the clin-
ical presentation are indicative familial hypercho-
lesterolemia (FH). His biochemical workup
excludes secondary causes. Genetic analysis
would conclude if he is homozygous or not. How-
ever, comparison of the most common primary
lipoprotein abnormalities in children [5] indicates
that his lipid profile is compatible with familial
hypercholesterolemia and different from Hyper-
apo-B – a variant of primary dyslipidaemia (See
Fig. 3).Treatment
He was treated with cholestyramine powder and
atorvastatin 10 mg daily for 3 months, but noL)
HDL
(mg/dL)
TG
(mg/dL)
Apo-A
(g/L)
Apo-B
(g/L)
Lp(a)
(g/L)
– –
29 200
26 136
25 115
17 69 0.54a 3.18b 1.57c
Figure 2. Photograph of the boy showing diffuse xanthoma at the
back.
Figure 3. Ultrasonogram showing fatty infiltration at the right tendo
Achilles.
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observed. Thereafter, the treatment was discon-
tinued by the guardians and the patient was with-
out medications for the next 4 years. On
subsequent contact after 4 years a course of ator-
vastatin 20 mg and ezetimibe 10 mg daily was of-
fered, but there was virtually no benefit again
after 3 months.Discussion
Familial hypercholesterolemia is a rare form of
genetic dyslipidaemia (an autosomal codominant
monogenic disease) with an incidence of about
1:500 in general population. Homozygous FH is
rare, with an occurrence rate of around 1 in 100
000 individuals. It is the commonest monogenic
disorder in Europe and North America. The dis-
ease is caused by a plethora of mutations in the
LDL-receptor gene (>300 mutations are listed in
the Human Gene Database). In some populations
(e.g. French Canadians, Afrikaners in South Africa
and the Lebanese), the incidence of FH is much
higher and certain specific LDL-receptor defects
are frequent because of founder effects [5,6].
The genetic mutations underlying FH affect the
production and processing of cell surface LDL
receptors resulting in impaired hepatic clearance
of circulating LDL particles, which leads to their
accumulation in bloodstream. Elevated LDL levels
are evident before birth and persist throughout
the lifespan [7].
Children with homozygous FH usually present
within the first decade of life, commonly on inves-
tigation due to the presence of physical findings
such as cutaneous xanthomas, xanthelasma, ten-
don xanthoma, corneal arcus as were observed
in the present case [8]. On the contrary, the het-
erozygous FH subjects are usually asymptomaticwith no abnormal physical findings, and are usu-
ally detected in adolescent period with elevated
LDL levels prompted by a family history of pre-
mature coronary artery disease (CAD) or dyslipi-
demia [9].
The lipid profile is strikingly abnormal in homo-
zygous FH subjects – the LDL cholesterol level of-
ten in the range of 15–25 mmol/L (500- to
1000 mg/dL), with reduced HDL cholesterol level
between 0.5 and 1.0 mmol/L (20–40 mg/dL)
which conforms well with that observed in our
subject. In heterozygous FH, the fasting lipopro-
tein (LDL cholesterol) level is usually above the
95th percentile for the age and gender, and is of-
ten associated with low HDL and normal triglycer-
ide levels [10].
High lipoprotein (a), a covalent complex of LDL
and the plasminogen-like apolipotrotein (a), has
also been considered an additional feature of FH
and confers additional risk of atherosclerosis. Het-
erozygous FH subjects showed levels of Lp (a) in
the range above the 90th percentile of healthy
white population levels, while levels in homozy-
gous patients were twice as high as in heterozy-
gous FH subjects.[6] The patient presented here
had Lp (a) levels >3-times the upper reference
limit.
Children with homozygous FH have severe and
early functional and structural cardiovascular dis-
eases including clinical CAD, aortic valve disease,
and atherosclerotic aortic, carotid and peripheral
vascular disease. On the other hand, heterozygous
FH subjects have been shown to have only abnor-
malities on noninvasive cardiovascular assess-
ment; e.g. greater intima-a thickness in carotid
artery [8]. The present case, however, did not
demonstrate such abnormalities.
The American Heart Association (AHA) identi-
fied homozygous FH subject as Tier 1 (Risk
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ommended treatment includes: complete cardio-
vascular assessment including plasma glucose,
blood pressure monitoring and noninvasive test-
ing to exclude clinical and subclinical cardiovascu-
lar disease; intensive interventions aiming to
reduce cholesterol level with high-dose statins in
combination with a cholesterol absorption inhibit-
ing agent, and low dose antithrombotic drug [10].
The index case had always had abnormal lipid
profile as regards to total cholesterol, triglycerides,
apolipoprotein A, apo-lipoprotein B. The family
history was suggestive of dyslipidaemia as evi-
denced by presence of xanthelasma and CABG
of the maternal grandfather. Although it is impor-
tant to know the lipid profiles of the other family
members to rule out FH, it was not possible to per-
form the test which was not widely available and
measured routinely at that time. A genetic analy-
sis also could not be done due to unavailability
of the test.
The boy had anti-lipid therapy at the 4 years of
age and repeated at 9 years of age, without any
significant clinical effect. Nevertheless, limited
treatment benefit with statins as observed can be
explained by the fact that statins reduce LDL cho-
lesterol in part by upregulation of LDL receptors,
which are usually limited in production or defec-
tive in those patients. Niacin therapy in addition
to statins has been found to be very effective in
the management of high LDL level [11].
However, the cornerstone of therapy for high le-
vel of cholesterol in this group of patients is plas-
mapheresis, especially LDL apheresis, but it is
expensive and has to be done twice weekly. Pa-
tients who are refractory to such therapies have
been successfully treated with liver transplant in
the developed countries.
The patient presented here had no success with
statins combined with agents inhibiting choles-
terol absorption (ezetimibe). Liver transplantation
is just becoming available in this country and is
beyond the reach of people without economic
means. The role of niacin as co-therapy in such
cases therefore needs to be elucidated.
The clinical features and biochemical parame-
ters in this nine-year old boy presented in this re-
port are consistent with homozygous familial
hypercholesterolemia without cardiovascular se-
quel. As the abnormal lipid profile is refractory
to conventional therapy, the role of other options(e.g. niacin or plasmapheresis) may be considered
before liver transplantation in such a case in
developing countries.Acknowledgement
None.
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